We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
David Lichtenstein

David R. Lichtenstein MD, FASGE, AGAF, FACG

Director, Interventional Endoscopy, Boston Medical Center; Professor of Medicine, Boston University School of Medicine, Boston, Massachusetts

Dr. David Lichtenstein is the Director of Advanced Gastrointestinal Endoscopy at Boston Medical Center and Professor of Medicine at Boston University School of Medicine. Dr. Lichtenstein received his medical doctorate from the University Of Pennsylvania School Of Medicine. He completed his internal medicine residency at Duke University Medical Center and a gastroenterology fellowship at Beth Israel Hospital in Boston.  He returned to Duke University Medical Center where he served as a Chief Resident in Internal Medicine followed by training in interventional endoscopy.

Dr. Lichtenstein is a recognized educator in the GI endoscopy community and currently serves on the ABIM Gastroenterology Board Exam Committee and is the Chair of the ASGE Technology Committee.  Dr. Lichtenstein served as the past president of the New England Endoscopy Society, the Chair of the Assessment and Certification Task Force that introduced the series of STARS educational programs for the ASGE and was a former Chair of the ERCP Section for the Annual Scientific Program Committee for Digestive Disease Week.  His research interests focus on advancing technologies for endoscopic management of complex GI disorders.  Most recently he is the principle investigator and advisory board member for an artificial intelligence device that improves detection of adenomatous colon polyps during colonoscopy and facilitates other aspects of quality metrics in colonoscopy.  He also serves on the Clinical Events Committee for a randomized controlled trial that evaluates an EUS-guided implant to reduce duodenal injury from augmented doses of radiation therapy to primary pancreatic cancer.

Disclosures

Dr. Lichtenstein reports the following:
  • Boston Scientific Corporation (Consultant)
  • Iterative Scopes (Consultant)
  • Olympus Corporation of the Americas (Speaker and consultant)
  • Ambu Corporation (Speaker and consultant)
  • Palette Life Sciences (Clinical Events Committee)